Targeting type I interferon–mediated activation restores immune function in chronic HIV infection

Anjie Zhen,1 Valerie Rezek,1 Cindy Youn,1 Brianna Lam,1 Nelson Chang,1 Jonathan Rick,1 Mayra Carrillo,1 Heather Martin,1 Saro Kasparian,1 Philip Syed,1 Nicholas Rice,1 David G. Brooks,2,3 and Scott G. Kitchen1

1Division of Hematology and Oncology, Department of Medicine, UCLA AIDS Institute, David Geffen School of Medicine, UCLA, Los Angeles, California, USA. 2Princess Margaret Cancer Center, Immune Therapy Program, University Health Network, Toronto, Ontario, Canada. 3Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Introduction
The HIV-specific T cell response is critical to control HIV replication following infection (1, 2). However, for a variety of reasons, including the insufficient generation and maintenance of functional T cell responses, T cells are incapable of clearing the infection (3, 4). T cell dysfunction due to cellular exhaustion arises during many chronic infections in response to ongoing antigen stimulation, which results in the expression of immunosuppressive factors including PD-1, TIM-3, and IL-10 (5–8). In addition to immunosuppressive mechanisms, chronic inflammation and immune activation may further foster T cell exhaustion, limiting control of infection (9, 10). In fact, chronic immune activation is a hallmark of HIV infection, and higher levels of activated CD4+ and CD8+ T cells are directly correlated with accelerated disease progression (11–14). Yet, the mechanisms underlying the emergence of T cell exhaustion and global immune activation due to chronic HIV infection have yet to be defined.

Accumulating evidence suggests that chronic type I interferon (IFN-I) signaling enhances immune activation and drives the expression of multiple inhibitory factors that inhibit antiviral immunity and contribute to viral persistence (5, 10, 15–17). IFN-I is critical for the initiation of antiviral responses, and blockade of IFN-I signaling during acute SIV infection in rhesus macaques resulted in a loss of antiviral control culminating in increased SIV replication, enhanced CD4+ T cell depletion, and accelerated disease progression (15, 18). Conversely, the same study also found that treatment with recombinant IFN-α (IFN-α2a) led to an IFN-desensitized state and accelerated disease progression despite initial heightened resistance to infection (15, 18, 19). Previous clinical trials treating HIV patients with pegylated IFN-α2a exhibited limited antiviral effects and no correlation between viral load decrease and plasma IFN-α2a concentration (15, 19–21). These results highlight the complex roles that IFN-I plays during antiviral responses. Importantly, the effects of IFN-I signaling on T cell responses and HIV replication, once persistent infection is established, at a time when the antiviral roles of IFN-I have been suggested to be blunted (22, 23), remain unclear.

Results
Expression of exhaustion and activation markers is elevated in T cells in chronically infected humanized BLT mice. Cellular immune responses in HIV-infected NOD SCID common γ chain–deficient (NSG)/humanized bone marrow–human fetal liver and thymus (BLT) mice (NSG-BLT mice) have been recently demonstrated to closely mirror those in humans (4, 24–30), making it a good model to study HIV immune pathology and immune-based therapies in vivo. To investigate immune activation and immune exhaustion in vivo, we generated NSG-BLT mice (for representative flow plots of human lymphocytes, see Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI89488DS1) and mock-infected or infected mice with HIV-1 and followed the expression of the immune inhibitory receptors PD-1 and TIM-3 and the activation markers HLA-DR and CD38 on CD8+ and CD4+ T cells (for representative staining of the markers, see Supplemental Figure 2). During chronic HIV infection (9–13 weeks), HLA-DR, CD38, PD-1, and TIM-3 were all elevated on human T cells, particularly on human CD8+ T cells, compared with T cells from uninfected mice generated from the same donor tissues (Figure 1, A–D, and Supplemental Figure 2A), indicating...
ongoing CD8+ T cell exhaustion and immune activation in the NSG-BLT model. In addition, we found that expression of TIM-3 gradually increased on T cells throughout HIV infection (Supplemental Figure 2C). Similar to previous reports in HIV-infected patients (1, 2) and lymphocytic choriomeningitis virus (LCMV)-infected mice, in HIV-infected NSG-BLT mice we found subsets of CD8+ T cells that overexpressed both PD-1 and TIM-3 exhaustion markers (3, 4), and they displayed significantly reduced ability to produce proinflammatory cytokines upon mitogen stimulation, suggesting impaired functions of these T cells (Figure 1, E and F).

IFN-I signaling is chronically elevated during HIV-1 infection. Chronic IFN-I signaling is strongly associated with immune activation and suppression in persistent virus infections (5–8). To examine the extent of IFN-I signaling in vivo, we longitudinally measured HIV RNA expression and the expression of the IFN-I-induced signature genes (ISGs) MX1 and OAS1 in both infected and uninfected mice. Humanized BLT mice support sustained HIV replication 7 weeks after infection (Figure 2A and refs. 9, 10) with gradual loss of CD4 cells and decreased CD4/CD8 ratios in the peripheral blood (Figure 2, B and C). MX1 expression levels in the peripheral blood increased rapidly, and both MX1 and OAS1 remained elevated in the blood and tissue throughout HIV infection (Figure 2, D and E) in comparison with uninfected mice. Thus, IFN-I–induced gene expression is maintained in multiple compartments following HIV infection in NSG-BLT mice.

IFN-I receptor blockade effectively lowers ISG expression and reverse immune exhaustion. To investigate the impact of chronic IFN-I signaling on inflammation and T cell exhaustion, HIV-infected BLT mice were treated beginning 13 weeks after infection with an anti-human IFN receptor 2 (IFNR2) blocking antibody or an isotype control antibody for 1 week. IFNR blockade lowered gene expression of the ISGs MX1, OAS1, and IRF7 (Figure 3A and Supplemental Figure 5A) in the peripheral blood, demonstrating that anti-IFNR treatment blocked human IFN-I signaling in vivo. IFNR blockade did not affect overall CD4+ T cell percentages among T cells, or CD4/CD8 T cell ratios or CD4 and CD8 T cell numbers in the peripheral blood (Supplemental Figure 3, A–D). IFNR blockade, but not the isotype antibody, significantly reduced levels of PD-1, TIM-3, and CD38 expression on CD8 T cells (Figure 3B, Supplemental Figure 4, and Supplemental Figure 5, B–E). Further, CD8+ T cells from IFNR-blocked mice produced higher levels of IFN-γ and IL-2 following mitogen PMA/ionomycin stimulation (Figure 3, C and D). To investigate whether HIV-specific CD8 T cell responses were improved, splenocytes from HIV-1–infected, isotype antibody–treated, or anti-IFNR2 antibody–treated mice were stimulated with an HIV clade B peptide pool (Gag, Env, Nef, and Pol) (11–14). IFNR blockade treatment elevated the percentage and number of HIV-specific IFN-γ-producing CD8+ T cells (Figure 3, E–G) as well as increasing the expression of IFN-γ produced by single HIV-specific cells (Figure 3H), indicating functional restoration of the HIV-specific T cell response when IFN-I signaling is alleviated. Interestingly, we also observed a reduction of HLA-DR on CD4+ T cells following IFNR blockade (Figure 3I), indicating a reduction in CD4+ T cell activation.

IFNR blockade effectively reduces viral load. With the decreased expression of exhaustion factors and increased levels of IFN-γ–producing HIV-specific CD8+ T cells, as well as reduction in CD4+ T cell activation, we then measured whether such improvement in CD8 T cell responses and overall immune activation reduction could lead to change in viral load. Interestingly, we found that IFNR blockade, but not isotype treatment, led to a reduction in virus loads when administered during the chronic stage of infection (Figure 4A).

Concurrent IFNR blockade and antiretroviral therapy result in faster viral suppression. In all, blocking IFN-I signaling during persistent viral infection can have multiple beneficial effects on immune responses and can lead to decreased HIV replication. To investigate the impact of blocking IFN-I signaling in conjunction with combination antiretroviral therapy (ART), humanized BLT mice were infected with HIVNL4-3-HSA, which is a replication-competent virus that contains a cell surface–expressed reporter gene (murine heat stable antigen [HSA]) whose detection is indicative of viral expression (5, 10, 15–17). Importantly, HIVNL4-3-HSA replicates with kinetics and titers analogous to that of the parental HIVNL4-3 in BLT mice (15, 18). Eight weeks after HIV infection, mice were treated with a daily regimen of ART (tenofovir disoproxil fumarate [TDF]/Emtricitabine [FTC]/raltegravir) for 3 weeks (n = 9), and another set of mice were treated with daily ART for 3 weeks including 1 week of concurrent IFNR blockade during ART treatment (n = 6). ART treatment reduced IFN-I signaling, and the combination of ART treatment with IFNR blockade resulted in a greater reduction in IFN-I signaling as shown by decreased expression of the ISGs MX1 and OAS1 (Figure 4B). Combined treatment of mice with ART and IFNR blockade also further reduced TIM-3 expression on CD8+ cells to levels similar to those in uninfected controls (Figure 3C). When stimulated with PMA/ionomycin, treatment with either IFNR blockade or ART alone restored CD8 production of cytokines, and CD8 cells from mice cotreated with ART and IFNR blockade produced a further improved level of cytokines that was similar to that in uninfected controls (Figure 3D). This suggests an additive benefit of ART and IFN-I blockade. ART treatment alone resulted in significant reduction of viral loads within 3 weeks of treatment compared with untreated infection (Figure 4E). Interestingly, blocking IFNR for 1 week in combination with ART led to a significantly greater reduction in HIV viral loads compared with IFNR blockade or ART alone (Figure 4, E and F, which shows viral load fold change after each treatment). This suggests that concurrent IFNR blockade during ART treatment of chronic HIV infection is beneficial to accelerate control of the virus.

Concurrent IFNR blockade and ART reduce levels of reactivatable viral reservoirs. The persistently infected, activation-inducible HIV reservoir represents a major obstacle to eradication. To determine how IFNR blockade affects the activation-inducible HIV reservoir, splenocytes were harvested from HIVNL4-3-HSA–infected mice treated with isotype antibody, anti-IFNR blocking antibody, ART, or ART with anti-IFNR blocking antibody. HIV reporter gene–expressing (i.e., productively infected) cells were removed by sorting, leaving only cells not expressing virus (15, 18, 19). We then measured HIV DNA copies from half of these cells and reactivated the other half with anti-CD3/anti-CD28 stimulation, in the presence of the protease inhibitor indinavir to prevent subsequent viral infection and spread in the culture. After 3 days, supernatant from the reactivation culture was collected for p24 ELISA assay to measure the production of viral particles and HIV RNA expression (15, 19–21) (for schematic outline of the viral reactivation assay, see Supplemental...
Figure 1. Chronic HIV infection results in elevated expression of activation and exhaustion markers and exhaustion of viral-specific CD8 cells. NSG-BLT humanized mice were constructed by implantation of fetal liver and fetal thymus as well as hematopoietic stem cells into the NSG mice. After human immune reconstitution, mice were mock-infected or infected with HIVNL4-3. Thirteen weeks after infection, whole blood from each mouse was collected, and cells were stained with anti-human antibodies CD45, CD3, CD4, CD8, TIM-3, PD-1, and HLA-DR and analyzed by flow cytometry. (A–D) Expression of HLA-DR, CD38, PD-1, and TIM-3 on human CD4 (A and B) and CD8 cells (C and D) was accessed by gating and by measurement of the percentage positive (A and C) and relative MFI (B and D) of marker expression (n = 3–5 mice per group and more than 1,000 events were acquired for each flow analysis). For relative MFI, data displayed are the mean relative MFI ± SEM of these markers as compared with the mean MFI of uninfected controls, showing differences between these populations. (E) Splenocytes from HIV-infected NSG mice were stimulated with mitogen for 6 hours with GolgiPlug and were stained for expression of CD8, TIM-3, PD-1, and intracellular expression of IL-2 and IFN-γ. More than 1,000 events were acquired for each flow analysis, and the experiment was repeated more than 3 times. (F) Summary and statistical analysis of the intracellular cytokine expression assay in E (n = 4–6 mice per group). The Mann-Whitney test was used to compare 2 groups (∗P < 0.05, **P < 0.005) (A–E), and the Kruskal-Wallis test was used for multiple comparisons (F, P < 0.05). Data represent mean ± SEM.
One of the hallmarks of HIV infection is chronic immune activation that promotes viral replication and CD4 depletion. In addition, chronic immune activation leads to the upregulation of inhibitory molecules and is widely believed to be one of the driving forces of immune exhaustion, in which effector cells lose their function and proliferation capacities (4, 24–30). Here we show, for the first time to our knowledge, that activation and exhaustion markers such as HLA-DR, CD38, PD-1, and TIM-3 are elevated in humanized BLT mice chronically infected with HIV-1 (Figure 1A) and that CD8 T cells expressing multiple suppressive receptors such as PD-1 and TIM-3 define an exhausted effector T cell population (Figure 1B) as observed in human HIV patients (1, 14) and mice chronically infected with LCMV (3). In addition, as in HIV-infected patients, we observed upregulated ISGs \( \text{MX1} \) and \( \text{OAS1} \) in chronically infected BLT mice compared with uninfected mice (Figure 2).

These results indicate that NSG-BLT mice infected with HIV can mirror immune activation and immune exhaustion observed in HIV-infected patients, making them an important animal model to study HIV immunopathogenesis and immunotherapy.

Given the complex activities of IFN-I during acute and chronic viral infection (18, 23), it is crucial to delineate the effect of IFN-I signaling during different phases of HIV infection, as improper modulation of anti-IFN or IFN-\( \alpha \) treatment during acute infection...
RESEARCH ARTICLE

**Figure A**

![Bar charts showing relative gene expression of MX1, OAS1, and IRF7](image)

**Figure B**

![Bar charts showing percentage of CD8 T cells with PD-1, TIM-3, and CD38](image)

**Figure C**

![Flow cytometry plot showing CD8 T cell response to IFN-α](image)

**Figure D**

![Bar charts showing IFN-γ and IL-2 MFI](image)

**Figure E**

![Flow cytometry plot showing CD8 T cell response to IFN-γ](image)

**Figure F**

![Bar charts showing percentage of CD8 T cells producing IFN-γ](image)

**Figure G**

![Bar charts showing number of CD8 T cells producing IFN-γ](image)

**Figure H**

![Bar charts showing IFN-γ MFI among CD8 T cells](image)

**Figure I**

![Bar charts showing HLA-DR MFI among CD4 T cells](image)
could have drastic effects, leading to both faster viral replication and disease progression (5, 7, 17, 18). Our results demonstrate that IFN-I signaling during chronic HIV infection is one of the driving forces underlying chronic inflammation, immune activation, and CD8+ T cell exhaustion and that blockade of IFN-I signaling could potentially improve T cell immune responses. Contrary to what was observed at the onset of acute SIV infection (18), where IFN antagonist resulted in loss of viral control and faster disease progression, we found that IFNAR blockade during the chronic stage of the HIV infection led to a reduction of immune activation, enhanced HIV-specific CD8+ T cell function, and decreased HIV plasma viral load. In addition, we observed a reduction in CD4 T cell activation upon IFNAR blockade, indicating that a chronically elevated level of IFN-I may have directly or indirectly contributed to the systematic activation of CD4 T cells. The reduced CD4+ T cell activation may have slowed the dissemination of the virus and in combination with enhanced immune competence contributed to the decrease of viral load. Furthermore, we demonstrate that concurrent ART and IFNAR blockade during chronic HIV infection accelerated viral suppression and ultimate reduction in the reactivatable HIV reservoir. The reduction of this reservoir may have resulted from better viral control or a release of viral expression that is suppressed by IFN-I responses. IFN-I signaling has been shown to suppress viral transcription in HIV-infected cells (31), and blockade of IFN-I signaling in the presence of ART treatment may reduce the establishment of persistently infected reservoirs. Our study highlights the multifaceted activities of IFNAR during viral infection and suggests that it may act as a double-edged sword during chronic HIV infection, fueling immune activation and viral dissemination. Further studies are needed to delineate the role of IFN-I signaling during persistent HIV infection and validate IFNAR blockade’s therapeutic potential for treating HIV infection, particularly in conjunction with ART.

Methods

**Humanized BLT mice.** Humanized mice were constructed as described previously (15, 30). In short, CD34+ cells were purified via magnetic cell sorting with CD34 microbeads (Miltenyi Biotec) from freshly obtained fetal liver tissues. NOD-SCID—common γ chain knockout (c−/−) mice (NSG mice) mice were sublethally irradiated (2.7 Gy) before the surgery and implanted with fetal liver and thymus derived from the same donor as the CD34+ cells. Afterward, mice were injected with 0.5 million to 1 million CD34+ cells. After 8–10 weeks, each mouse was bled retro-orbitally to check human immune cell engraftment. Each donor tissue can be used to construct 15–25 mice. Mice that had more than 50% human lymphocytes in the peripheral blood mononuclear cells were used for HIV infection and further experiments. A standard healthy uninfected humanized BLT mouse contains 0.5 million to 2 million human lymphocytes per milliliter in the blood and 10 million to 30 million human lymphocytes per milliliter in the spleen.

**Antibodies and flow cytometry.** The following antibodies were used in flow cytometry: CD45 (clone HI30), CD3 (clone OKT3), CD4 (clone RPA-T4), CD8 (clone SK1), CD38 (clone HIT2), HLA-DR (clone L240), PD-1 (clone eBioJ105) (eBioscience), TIM-3 (clone F83-2E2) (Biolegend), and anti-HIV-1 core antigen clone KC57 (Beckman Coulter). Antibody for cell surface markers were conjugated to FITC, PE, PerCP-Cy5.5, PE-Cy5, PE-Cy7, EVD, APC, APC-eFluor 780, Alexa Fluor 700, eFluor 405, Pacific Orange, or Pacific Blue in appropriate combination. The cells were acquired using an LSRFortessa flow cytometer and FACSDiva software (BD Biosciences). Data were analyzed using FlowJo software. At least 1,000 cells were acquired for each analysis, and each representative flow plot was repeated more than 3 times.

**In vitro cytokine assay.** We assessed purified splenocytes from BLT mice for production of IFN-γ or IL-2 by intracellular staining and flow cytometry. Cells were stimulated with PMA/ionomycin for 6 hours in the presence of GolgiPlug (BD Biosciences) or treated with HIV-1 clade B Env, Gag, Pol peptide pool (from NIH AIDS Reagent Program, www.aidsreagent.org) overnight and an additional 6 hours of GolgiPlug treatment. Cells were then stained with CD45, CD3, CD8, IFN-γ, and IL-2 (eBioscience).

**ART treatment and IFNAR blockade treatment.** For ART, HIV-infected mice were treated by daily injection of 500 μL of TDF (8.75 mg/kg)/ FTC (13 mg/kg)/raltegravir (17.5 mg/kg) dissolved in PBS. For IFNAR blockade treatment, HIV-infected mice, either untreated or treated with ART, were treated with 100 μg anti-IFNAR2 blocking antibody (clone MMHAR-2) or an IgG isotype control (eBioscience) once every 2 days by i.p. injection for 1 week. One hundred micrograms every 2 days was chosen because it was the minimum dosage to maintain lower ISG expression in the humanized BLT mice (data not shown). A treatment course of 1 week was chosen because it has been shown to effectively target IFN-I signaling in LCMV-infected mice (5). For mice that were treated with both ART and IFNAR blockade, the anti-IFNAR2 antibody was given concurrently with the ART regiment at the last week of ART treatment.

**Real-time PCR.** To measure the levels of cell-associated HIV RNA and the ISGs MX1 and OAS1, with HPRT1 as an internal control, splenocytes and peripheral blood mononuclear cells were harvested for RNA extraction and making of cDNA using the High-Capacity cDNA RESEARCH ARTICLE

The Journal of Clinical Investigation
Blood was then spun at 1,200 g to collect plasma supernatant. Viral RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen), and 1-step real-time PCR was performed using TaqMan RNA-To-Ct 1-Step Kit (Thermo Fisher Scientific) with the following primers and probe:

- HIV-1 forward primer: 5′-CAATGGCAGCAATTTCACCA-3′
- HIV-1 reverse primer: 5′-GAATGCCAAATTCCTGCTTGA-3′
- HIV-1 probe: 5′-[6-FAM]CCCACCAACAGGCGGCCTTAACTG[Tamra-Q]-3′

Assay for reactivatable virus. The assay for reactivatable virus was performed similarly to what was previously reported (15, 19). In short, Reverse Transcription Kit (Thermo Fisher Scientific). Real-time PCR was performed using the following primers and probes: HIV-1 forward primer: 5′-CAATGGCAGCAATTTCACCA-3′; HIV-1 reverse primer: 5′-GAATGCCAAATTCCTGCTTGA-3′; HIV-1 probe: 5′-[6-FAM]CCCACCAACAGGCGGCCTTAACTG[Tamra-Q]-3′; Single Tube TaqMan Gene Expression Assays: human HPRT1 (Hs01003267_m1), MX1 (Hs00895608_m1), and OAS1 (Hs00973635_m1).

Plasma viral load. To measure HIV plasma viral load, blood was collected from mice via retro-orbital bleeding or heart puncture at end point. Blood was then spun at 1,200 g to collect plasma supernatant. Viral RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen), and 1-step real-time PCR was performed using TaqMan RNA-To-Ct 1-Step Kit (Thermo Fisher Scientific) with the following primers and probe: HIV-1 forward primer: 5′-CAATGGCAGCAATTTCACCA-3′; HIV-1 reverse primer: 5′-GAATGCCAAATTCCTGCTTGA-3′; HIV-1 probe: 5′-[6-FAM]CCCACCAACAGGCGGCCTTAACTG[Tamra-Q]-3′.

Assay for reactivatable virus. The assay for reactivatable virus was performed similarly to what was previously reported (15, 19). In short,
mice were infected with HIV
\textsubscript{NL4-3HSAT}, which will allow actively infected cells to express mouse heat stable antigen (HSA). After the mice were sacrificed, splenocytes were isolated, and HSA- cells were depleted using biotin-conjugated anti-HSA antibody (eBioscience) and Streptavridin Microbeads (Miltenyi Biotec). HSA- cells were then activated with anti-CD3 (plate bound) and anti-CD28 (soluble) and indinavir for 3 days. Supernatant from activated cells was collected and purified for HIV p24 antigen ELISA assay, and cells were collected for HIV DNA and RNA real-time PCR analysis.

Statistics. A total of 5 independent cohorts of mice (n = 15–30 total mice, each constructed from the same donor tissues) were used in this study for various experiments. Two cohorts were pooled for comparing uninfected and infected mice. Three cohorts were pooled for comparing uninfected mice versus infected mice treated with isotype antibody or IFNR blockade versus infected mice treated with ART and isotype antibody or IFNR blockade. To pool mice from different cohorts, each measurement (ISG expression level or MFI of activation/exhaustion markers) was first normalized to the uninfected controls of the cohort. Each analysis, including those shown in bar graphs such as the MFI comparison or real-time PCR, contains at least 4–7 biological replicates (number of mice). For flow analysis of CD4 and CD8 cells, at least 1,000 events were acquired for the population of interest. For analysis of data that contains more than 2 groups (depicted in Figure 1C; Figure 3, A and B; and Figure 4, B–D, F, and G), the Kruskal-Wallis test was performed to compare samples; and all of these data have P value less than 0.05. To compare statistical significance between 2 groups, Mann-Whitney U tests were used. P values less than 0.05 by Kruskal-Wallis or Mann-Whitney were considered significant. Consultation on statistical analysis was performed with the UCLA Center for AIDS Research Biostatistics Core and the UCLA Biostatistics Department.

Study approval. Peripheral blood mononuclear cells were obtained at UCLA in accordance with UCLA IRB-approved protocols under written informed consent using an IRB-approved written consent form by the UCLA Center for AIDS Research Virology Laboratory and distributed for this study without personal identifying information. Human fetal tissue was purchased from Advanced Biosciences Resources or from StemExpress and was obtained without identifying information and did not require IRB approval for its use. Animal research described in this article was performed under the written approval of the UCLA Animal Research Committee in accordance with all federal, state, and local guidelines. All surgeries were performed under ketamine/xylazine and isoflurane anesthesia, and all efforts were made to minimize animal pain and discomfort.

Author contributions
AZ designed the experiments. AZ, VC, CY, BL, NC, JR, MC, HM, SK, PS, and NR performed the experiments. AZ analyzed the data. AZ, DGB, and SGK wrote the manuscript.

Acknowledgments
We thank Jerome Zack and Matthew Marsden for provision of ART drugs and for helpful discussions. This work was funded by NIH grants AI078806 and AI10306-01 (to SGK) and AI085043 (to DGB); the UCLA Center for AIDS Research (P30AI28697); the California Center for Regenerative Medicine (TR4-06845); the UC Multicampus Research Programs and Initiatives, California Center for Antiviral Drug Discovery, and California HIV/AIDS Research Program (F12-LA-215 to AZ); NIH grant T32-AI060567 (to AZ); and the UCLA AIDS Institute and UCLA Center for AIDS Research Research (AI28697 to AZ). The flow cytometry machine used in the study was purchased through a Pendleton Foundation grant.

Address correspondence to: Scott G. Kitchen, UCLA AIDS Institute, 615 Charles E. Young Drive South, Los Angeles, California 90095, USA. Phone: 310.983.1251; E-mail: skitchen@ucla.edu. Or to: David G. Brooks, Princess Margaret Cancer Center, 610 University Avenue, Toronto, Ontario MS2M9, Canada. Phone: 416.634.7238; E-mail: dbrooks@uhnresearch.ca.


